I think you mean Pluvicto, a radioligand that uses a radioactive isotope (Lutetium 177) which attaches to cancer cells which express PSMA anywhere in the body and damages them. But Pluvicto ONLY targets PSMA-positive cancer cells--it is not effective against cancer cells which do not express PSMA. Also, Pluvicto was not described to us as a "cure option" by the team at Mayo. It is generally accepted that Stage 4/metastatic prostate cancer cannot be cured, only controlled and sent into remission, though sometimes for many years.